Precipio, Inc. (PRPO)
- Previous Close
6.05 - Open
6.04 - Bid 5.19 x 100
- Ask 7.15 x 100
- Day's Range
6.04 - 6.30 - 52 Week Range
4.75 - 14.80 - Volume
1,957 - Avg. Volume
3,729 - Market Cap (intraday)
9.229M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-4.51 - Earnings Date May 15, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
www.precipiodx.com51
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRPO
Performance Overview: PRPO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRPO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRPO
Valuation Measures
Market Cap
9.23M
Enterprise Value
8.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.54
Price/Book (mrq)
0.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.51%
Return on Assets (ttm)
-24.05%
Return on Equity (ttm)
-38.01%
Revenue (ttm)
15.2M
Net Income Avi to Common (ttm)
-5.85M
Diluted EPS (ttm)
-4.51
Balance Sheet and Cash Flow
Total Cash (mrq)
1.5M
Total Debt/Equity (mrq)
7.73%
Levered Free Cash Flow (ttm)
-2.75M
Research Analysis: PRPO
Company Insights: PRPO
PRPO does not have Company Insights